Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2010 - 2026)

Acadia Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $851.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 24.92% year-over-year to $851.5 million; the TTM figure through Mar 2026 stood at $851.5 million (up 24.92% YoY), while the FY2025 annual figure was $819.7 million, up 8.43% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $851.5 million, up from $819.7 million in the prior quarter.
• The five-year high for Cash & Current Investments was $851.5 million in Q1 2026, with the low at $345.9 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $470.5 million (2024), against an average of $562.0 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments decreased 22.81% in 2022, then jumped 72.26% in 2024.
• Acadia Pharmaceuticals' Cash & Current Investments stood at $416.8 million in 2022, then increased by 5.29% to $438.9 million in 2023, then surged by 72.26% to $756.0 million in 2024, then increased by 8.43% to $819.7 million in 2025, then rose by 3.88% to $851.5 million in 2026.
• Business Quant data shows ACAD's Cash & Current Investments at $851.5 million in Q1 2026, $819.7 million in Q4 2025, and $847.0 million in Q3 2025.